Farmacología cardiovascular: acceso abierto

Abstracto

Percutaneous Coronary Intervention in Patients with Heparin Induced Thrombocytopenia: Case Report and Review of Literature

Narasimha D, Jutzy K and Hilliard A*

Heparin Induced Thrombocytopenia (HIT) is a rare disorder, which manifests as acute onset thrombocytopenia within five to fifteen days after exposure to heparin. The milder version of the disease may manifest as asymptomatic thrombocytopenia, which resolves with cessation of heparin. The more severe form presents with arterial and venous thrombi, profound thrombocytopenia and is associated with devastating consequences such as myocardial infarction, stroke, limb ischemia etc. The management of patients with HIT undergoing revascularization in the form of Percutaneous Coronary Intervention (PCI) and/or Coronary Artery Bypass Grafting (CABG) can be challenging and complicated by acute stent thrombosis and early graft closure. Management strategy consists of immediate discontinuation of all heparin products, alternative anticoagulation, and lifelong avoidance of heparin products. Here we describe the various challenges specifically associated with coronary re-vascularization in these patients, and the current treatment options available.